2026 ICD-10-CM Diagnosis Code D39.2Neoplasm of uncertain behavior of placenta

ICD-10-CM CodesC00–D49D37-D48D39

ICD-10-CM D39.2
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

D39.2 is a billable ICD-10-CM diagnosis code for neoplasm of uncertain behavior of placenta. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 736 through 741, 754 through 756. The code is restricted by the Medicare Code Editor to maternity cases (age 9 through 64). Coders also document this condition as gestational trophoblastic disease. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Neoplasms of unspecified nature or uncertain behavior.

Code Identity

ICD-10-CM Code
D39.2
Billable Status
Yes — Valid for Submission
Code Describes
Neoplasm of uncertain behavior of placenta
Short Description
Neoplasm of uncertain behavior of placenta
Same as the full description in the CMS dataset.
Parent Code
Neoplasm of uncertain behavior of female genital organs

Code Classification

ChapterC00–D49Neoplasms
SectionD37-D48Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes
CategoryD39Neoplasm of uncertain behavior of female genital organs
This CodeD39.2Neoplasm of uncertain behavior of placenta

Code EditsBilling

Medicare Code Editor checks that affect claim validity for D39.2.

The Medicare Code Editor detects inconsistencies in maternity cases by checking a patient's age and any diagnosis on the patient's record. The maternity code edits apply to patients age ange is 9–64 years inclusive (e.g., diabetes in pregnancy, antepartum pulmonary complication).

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Gestational trophoblastic disease
  • Gestational trophoblastic neoplasia
  • Invasive hydatidiform mole
  • Neoplasm of placenta
  • Neoplasm of uncertain behavior of placenta
  • Placental site trophoblastic tumor

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Inclusion Terms

  • Chorioadenoma destruens
  • Invasive hydatidiform mole
  • Malignant hydatidiform mole

Type 1 Excludes

  • hydatidiform mole NOS O01.9

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Chorioadenoma(destruens)
    • Hydatidiform mole(benign) (complicating pregnancy) (delivered) (undelivered)
      • invasive
    • Hydatidiform mole(benign) (complicating pregnancy) (delivered) (undelivered)
      • malignant
    • Mola destruens
    • Mole(pigmented)
      • destructive
    • Mole(pigmented)
      • hydatid, hydatidiform (benign) (complicating pregnancy) (delivered) (undelivered)
        • invasive
    • Mole(pigmented)
      • hydatid, hydatidiform (benign) (complicating pregnancy) (delivered) (undelivered)
        • malignant
    • Mole(pigmented)
      • invasive (hydatidiform)
    • Mole(pigmented)
      • malignant
        • meaning
          • malignant hydatidiform mole
    • Tumor
      • placental site trophoblastic
    • Tumor
      • trophoblastic, placental site

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR NEO072
Neoplasms of unspecified nature or uncertain behavior
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Abruptio Placentae

    premature separation of the normally implanted placenta from the uterus. signs of varying degree of severity include uterine bleeding, uterine muscle hypertonia, and fetal distress or fetal death.
  • Annexin A3

    a protein of the annexin family that catalyzes the conversion of 1-d-inositol 1,2-cyclic phosphate and water to 1-d-myo-inositol 1-phosphate.
  • Annexin A4

    protein of the annexin family originally isolated from the electric organ of the electric ray torpedo marmorata. it has been found in a wide range of mammalian tissue where it is localized to the apical membrane of polarized epithelial cells.
  • Annexin A5

    a protein of the annexin family isolated from human placenta and other tissues. it inhibits cytosolic phospholipase a2, and displays anticoagulant activity.
  • Cadherins

    calcium-dependent cell adhesion proteins. they are important in the formation of adherens junctions between cells. cadherins are classified by their distinct immunological and tissue specificities, either by letters (e- for epithelial, n- for neural, and p- for placental cadherins) or by numbers (cadherin-12 or n-cadherin 2 for brain-cadherin). cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.
  • Chorionic Villi

    threadlike vascular projections of the chorion. chorionic villi may be free or embedded within the decidua forming the site for exchange of substances between fetal and maternal blood (placenta).
  • Cord Blood Stem Cell Transplantation

    transplantation of stem cells collected from the fetal blood remaining in the umbilical cord and the placenta after delivery. included are the hematopoietic stem cells.
  • Eutheria

    mammals which nourish their young in utero by means of a complex placenta, and give birth to their young alive. they include primates; carnivora, whales; ruminants; bats; and rodents.
  • Folate Receptor 2

    a subtype of gpi-anchored folate receptors that is expressed in placenta and hematopoietic cells.
  • Ichthyosis, X-Linked

    chronic form of ichthyosis that is inherited as a sex-linked recessive trait carried on the x-chromosome and transmitted to the male offspring. it is characterized by severe scaling, especially on the extremities, and is associated with steroid sulfatase deficiency.
  • Perilipin-3

    a perilipin that localizes to lipid droplets; cytoplasm; endosomes; and plasma membrane, especially in macrophages. it functions as a transporter of free fatty acids to lipid droplets to promote their biogenesis and growth. it is also required for the transport of the mannose-6-phosphate receptor from endosomes to the trans-golgi network. its structure consists of four helix bundles that interact with the hydrophobic lipid droplet surface.
  • Placenta

    a highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products. it includes a fetal portion (chorionic villi) derived from trophoblasts and a maternal portion (decidua) derived from the uterine endometrium. the placenta produces an array of steroid, protein and peptide hormones (placental hormones).
  • Placenta Accreta

    abnormal placentation in which all or parts of the placenta are attached directly to the myometrium due to a complete or partial absence of decidua. it is associated with postpartum hemorrhage because of the failure of placental separation.
  • Placenta Diseases

    pathological processes or abnormal functions of the placenta.
  • Placenta Growth Factor

    an angiogenic protein belonging to the vascular endothelial growth factor family of growth factors originally isolated and cloned from human placental cdna library. there are four isoforms of plgf 1-4 which result from alternative splicing. placenta growth factor is secreted as a glycosylated homodimer which acts as a mitogen for endothelial cells, and its expression is markedly upregulated during hypoxia and in tissue inflammation and cancer.
  • Placenta Previa

    abnormal placentation in which the placenta implants in the lower segment of the uterus (the zone of dilation) and may cover part or all of the opening of the cervix. it is often associated with serious antepartum bleeding and premature labor.
  • Placenta, Retained

    a placenta that fails to be expelled after birth of the fetus. a placenta is retained when the uterus fails to contract after the delivery of its content, or when the placenta is abnormally attached to the myometrium.
  • Placental Circulation

    the circulation of blood, of both the mother and the fetus, through the placenta.
  • Placental Extracts

    extracts prepared from placental tissue; they may contain specific but uncharacterized factors or proteins with specific activities.
  • Placental Function Tests

    methods used for the assessment of placental function.
  • Placental Hormones

    hormones produced by the placenta include chorionic gonadotropin, and placental lactogen as well as steroids (estrogens; progesterone), and neuropeptide hormones similar to those found in the hypothalamus (hypothalamic hormones).
  • Placental Insufficiency

    failure of the placenta to deliver an adequate supply of nutrients and oxygen to the fetus.
  • Placental Lactogen

    a polypeptide hormone of approximately 25 kda that is produced by the syncytiotrophoblasts of the placenta, also known as chorionic somatomammotropin. it has both growth hormone and prolactin activities on growth, lactation, and luteal steroid production. in women, placental lactogen secretion begins soon after implantation and increases to 1 g or more a day in late pregnancy. placental lactogen is also an insulin antagonist.
  • Placentation

    the development of the placenta, a highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products between mother and fetus. the process begins at fertilization, through the development of cytotrophoblasts and syncytiotrophoblasts, the formation of chorionic villi, to the progressive increase in blood vessels to support the growing fetus.
  • Plasminogen Inactivators

    important modulators of the activity of plasminogen activators. the inhibitors belong to the serpin family of proteins and inhibit both the tissue-type and urokinase-type plasminogen activators.
  • Pregnancy Proteins

    proteins produced by organs of the mother or the placenta during pregnancy. these proteins may be pregnancy-specific (present only during pregnancy) or pregnancy-associated (present during pregnancy or under other conditions such as hormone therapy or certain malignancies.)
  • Pregnancy Trimester, First

    the beginning third of a human pregnancy, from the first day of the last normal menstrual period (menstruation) through the completion of 14 weeks (98 days) of gestation.
  • S100 Calcium-Binding Protein A4

    an s100 protein characterized by four helix bundles that form n- and c-terminal ef hand motifs. it functions as a homodimer and interacts with both intracellular and extracellular signaling proteins. aberrant s100a4 activity is associated with neoplasm metastasis; fibrosis; and rheumatoid arthritis.
  • Trophoblastic Tumor, Placental Site

    an uncommon variant of choriocarcinoma. it is composed almost entirely of mononuclear cytotrophoblasts (trophoblasts). because its secretion of hcg (chorionic gonadotropin) is low, a large tumor may develop before the hcg can be detected.
  • Umbilical Cord Clamping

    method of placing clamps on the umbilical cord before cutting after birth.
  • Gestational Trophoblastic Disease

    a group of diseases arising from pregnancy that are commonly associated with hyperplasia of trophoblasts (trophoblast) and markedly elevated human chorionic gonadotropin. they include hydatidiform mole, invasive mole (hydatidiform mole, invasive), placental-site trophoblastic tumor (trophoblastic tumor, placental site), and choriocarcinoma. these neoplasms have varying propensities for invasion and spread.

Table of NeoplasmsClinical

Anatomical sites in the Table of Neoplasms that reference this code family.

SiteMalig.
Primary
Malig.
Secondary
Ca
in situ
BenignUncertainUnspec.
fetal membraneC58C79.82D07.0D26.7D39.2D49.59
placentaC58C79.82D07.0D26.7D39.2D49.59

Patient EducationClinical

Health Problems in Pregnancy

A health problem in pregnancy is any disease or condition that could affect your health or the health of your fetus. Some health problems may make it more likely that you will have a high-risk pregnancy. A high-risk pregnancy is one in which you, your fetus, or both are at higher risk for health problems than in a typical pregnancy.

The full article covers:

  • What are health problems in pregnancy?
  • What raises my risk for health problems during pregnancy?
  • Can chronic health conditions cause problems in pregnancy?
  • Can health problems in pregnancy be prevented?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert D39.2 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
236.1 Unc behav neo placenta
Exact Match The mapping is direct, with no qualifiers.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About D39.2Overview

Is D39.2 (Neoplasm of uncertain behavior of female genital organs) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report neoplasm of uncertain behavior of placenta on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does D39.2 group to?

When neoplasm of uncertain behavior of placenta is the principal diagnosis on an inpatient stay, it groups to MS-DRG 736, 737, 738, 739, 740, 741, 754, 755, 756, with relative weights from 0.9605 to 3.5745 depending on complications. Higher weights mean higher Medicare reimbursement.

Who can D39.2 be reported for?

The Medicare Code Editor checks neoplasm of uncertain behavior of placenta against patient demographics: this code is intended for maternity cases (age 9 through 64). Claims outside these limits are flagged as inconsistent.

What is the ICD-9 equivalent of D39.2?

Under the General Equivalence Mappings, neoplasm of uncertain behavior of placenta converts to ICD-9-CM 236.1 (unc behav neo placenta). The mapping is a direct match.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.